{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:13:51Z","timestamp":1791807231126,"version":"4.3.4"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>With new legal abortion restrictions, timing of prenatal care initiation is critical to allow for discussion of reproductive options among pregnancies exposed to teratogenic medications.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate the prevalence of prenatal exposure to teratogenic medications and prenatal care initiation across gestational weeks.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This descriptive, population-based cross-sectional study used health encounter data from a national sample of individuals with employer-sponsored health insurance. A validated algorithm identified pregnancies among persons identifying as female that ended with a live or nonlive outcome between January 2017 and December 2019. Data were analyzed from December 2022 to December 2023.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Prenatal exposure to any of 137 teratogenic medications, measured via pharmacy and medical claims. Measurement of prenatal care initiation was adapted from the Children\u2019s Health Care Quality Measures.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Prevalence of prenatal exposure to teratogens and prenatal care initiation by gestational week. Timing of prenatal teratogenic exposure was compared with timing of prenatal care initiation and legal abortion cutoffs.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 639\u202f994 pregnancies, 472\u202f472 (73.8%; 95% CI, 73.7%-73.9%) had a live delivery (mean [SD] age, 30.9 [5.4] years) and 167\u202f522 (26.2%; 95% CI, 26.1%-26.3%) had a nonlive outcome (mean [SD] age, 31.6 [6.4] years). Of pregnancies with live deliveries, 5.8% (95% CI, 5.7%-5.8%) were exposed to teratogenic medications compared with 3.1% (95% CI, 3.0%-3.2%) with nonlive outcomes. Median time to prenatal care was 56 days (IQR, 44-70 days). By 6 weeks\u2019 gestation, 8186 pregnancies had been exposed to teratogenic medications (25.2% [95% CI, 24.7%-25.7%] of pregnancies exposed at any time during gestation; 1.3% [95% CI, 1.3%-1.3%] of all pregnancies); in 6877 (84.0%; 95% CI, 83.2%-84.8%), prenatal care was initiated after 6 weeks or not at all. By 15 weeks, teratogenic exposures had occurred for 48.9% (95% CI, 48.4%-49.5%) of all teratogen-exposed pregnancies (2.5% [2.4-2.5] of all pregnancies); prenatal care initiation occurred after 15 weeks for 1810 (16.8%; 95% CI, 16.1%-17.5%) with live deliveries and 2975 (58.3%; 95% CI, 56.9%-59.6%) with nonlive outcomes. Teratogenic medications most used within the first 15 gestational weeks among live deliveries included antiinfectives (eg, fluconazole), anticonvulsants (eg, valproate), antihypertensives (eg, lisinopril), and immunomodulators (eg, mycophenolate). For nonlive deliveries, most antihypertensives were replaced by vitamin A derivatives.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cross-sectional study, most exposures to teratogenic medications occurred in early pregnancy and before prenatal care initiation, precluding prenatal risk-benefit assessments. Prenatal care commonly occurred after strict legal abortion cutoffs, prohibiting consideration of pregnancy termination if concerns about teratogenic effects arose.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.54298","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T16:32:43Z","timestamp":1706805163000},"page":"e2354298","source":"Crossref","is-referenced-by-count":11,"title":["Prenatal Care Initiation and Exposure to Teratogenic Medications"],"prefix":"10.1001","volume":"7","author":[{"given":"Almut G.","family":"Winterstein","sequence":"first","affiliation":[{"name":"Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, University of Florida, Gainesville"},{"name":"Epidemiology, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanning","family":"Wang","sequence":"additional","affiliation":[{"name":"Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"Health Outcomes & Biomedical Informatics, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole E.","family":"Smolinski","sequence":"additional","affiliation":[{"name":"Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy N.","family":"Thai","sequence":"additional","affiliation":[{"name":"Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, University of Florida, Gainesville"},{"name":"Faculty of Pharmacy, HUTECH University, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Ewig","sequence":"additional","affiliation":[{"name":"Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja A.","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"issue":"2","key":"zoi231589r3","doi-asserted-by":"publisher","first-page":"263.e1","DOI":"10.1016\/j.ajog.2022.01.004","article-title":"Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies.","volume":"227","author":"Sarayani","year":"2022","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"zoi231589r6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40264-021-01053-3","article-title":"Real-world fetal exposure to acne treatments in the United States: a retrospective analysis from 2006 to 2015.","volume":"44","author":"Albogami","year":"2021","journal-title":"Drug Saf"},{"issue":"10","key":"zoi231589r7","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jamadermatol.2019.1388","article-title":"US Food and Drug Administration reports of pregnancy and pregnancy-related adverse events associated with isotretinoin.","volume":"155","author":"Tkachenko","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"17","key":"zoi231589r8","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1001\/jama.2022.11489","article-title":"Threats to evidence-based care with teratogenic medications in states with abortion restrictions.","volume":"328","author":"Rubin","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"zoi231589r9","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.7326\/M22-2246","article-title":"Unintended consequences of SCOTUS abortion decision for patients with rheumatic diseases.","volume":"175","author":"Clowse","year":"2022","journal-title":"Ann Intern Med"},{"key":"zoi231589r12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.contraception.2021.10.006","article-title":"Home pregnancy test use and timing of pregnancy confirmation among people seeking health care.","volume":"107","author":"Ralph","year":"2022","journal-title":"Contraception"},{"issue":"4","key":"zoi231589r13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s10995-016-2155-1","article-title":"Trends in timing of pregnancy awareness among US women.","volume":"21","author":"Branum","year":"2017","journal-title":"Matern Child Health J"},{"issue":"8","key":"zoi231589r14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"8","key":"zoi231589r15","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/bmjqs-2019-010098","article-title":"Comparative effectiveness of risk mitigation strategies to prevent fetal exposure to mycophenolate.","volume":"29","author":"Sarayani","year":"2020","journal-title":"BMJ Qual Saf"},{"issue":"6","key":"zoi231589r16","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/pds.v29.6","article-title":"Risk of pregnancy loss in patients exposed to mycophenolate compared to azathioprine: a retrospective cohort study.","volume":"29","author":"Thai","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"zoi231589r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2022.10.005","article-title":"Risk of fetal or neonatal death or neonatal intensive care unit admission associated with gadolinium magnetic resonance imaging exposure during pregnancy.","author":"Winterstein","year":"2023","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"zoi231589r18","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/hesr.2007.42.issue-2","article-title":"Development of an algorithm to identify pregnancy episodes in an integrated health care delivery system.","volume":"42","author":"Hornbrook","year":"2007","journal-title":"Health Serv Res"},{"issue":"2","key":"zoi231589r19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192033","article-title":"Inferring pregnancy episodes and outcomes within a network of observational databases.","volume":"13","author":"Matcho","year":"2018","journal-title":"PLoS One"},{"issue":"11","key":"zoi231589r20","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1002\/pds.v29.11","article-title":"Validation of algorithms to estimate gestational age at birth in the Medicaid Analytic eXtract-Quantifying the misclassification of maternal drug exposure during pregnancy.","volume":"29","author":"Zhu","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"zoi231589r21","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2147\/CLEP.S269400","article-title":"Impact of the transition from ICD-9-CM to ICD-10-CM on the identification of pregnancy episodes in US health insurance claims data.","volume":"12","author":"Sarayani","year":"2020","journal-title":"Clin Epidemiol"},{"issue":"11","key":"zoi231589r22","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s40264-021-01113-8","article-title":"Validating claims-based algorithms determining pregnancy outcomes and gestational age using a linked claims-electronic medical record database.","volume":"44","author":"Moll","year":"2021","journal-title":"Drug Saf"},{"issue":"3","key":"zoi231589r23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/ajmg.c.v157.3","article-title":"Evolving knowledge of the teratogenicity of medications in human pregnancy.","volume":"157C","author":"Adam","year":"2011","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"8","key":"zoi231589r24","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/bdra.v94.8","article-title":"Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? a critical review of the evidence.","volume":"94","author":"Polifka","year":"2012","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"2","key":"zoi231589r25","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1161\/HYPERTENSIONAHA.112.196352","article-title":"Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review.","volume":"60","author":"Bullo","year":"2012","journal-title":"Hypertension"},{"issue":"4","key":"zoi231589r27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.7326\/M22-1743","article-title":"Assessment of the risk evaluation and mitigation strategy (REMS) for phentermine-topiramate to prevent exposure during pregnancy.","volume":"176","author":"Sarayani","year":"2023","journal-title":"Ann Intern Med"},{"issue":"5","key":"zoi231589r30","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1007\/s10995-006-0100-4","article-title":"Preconception care for improving perinatal outcomes: the time to act.","volume":"10","author":"Atrash","year":"2006","journal-title":"Matern Child Health J"},{"issue":"1","key":"zoi231589r31","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1097\/AOG.0000000000003013","article-title":"ACOG Committee Opinion No. 762: prepregnancy counseling.","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"2","key":"zoi231589r32","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/hesr.v58.2","article-title":"Preconception, interconception, and reproductive health screening tools: a systematic review.","volume":"58","author":"Ren","year":"2023","journal-title":"Health Serv Res"},{"issue":"4","key":"zoi231589r33","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.amepre.2021.03.021","article-title":"Prepregnancy counseling among US women with diabetes and hypertension, 2016-2018.","volume":"61","author":"Marshall","year":"2021","journal-title":"Am J Prev Med"},{"issue":"9","key":"zoi231589r34","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1056\/NEJMsa1506575","article-title":"Declines in unintended pregnancy in the United States, 2008-2011.","volume":"374","author":"Finer","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi231589r35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/EDE.0000000000001559","article-title":"Development and validation of algorithms to estimate live birth gestational age in Medicaid Analytic eXtract data.","volume":"34","author":"Zhu","year":"2023","journal-title":"Epidemiology"},{"key":"zoi231589r36","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000001302","article-title":"A pharmacoepidemiologic approach to evaluate real-world effectiveness of hormonal contraceptives in the presence of drug-drug interactions.","author":"Sarayani","year":"2021","journal-title":"Epidemiology"},{"issue":"3","key":"zoi231589r37","first-page":"1","article-title":"Timing and adequacy of prenatal care in the United States, 2016.","volume":"67","author":"Osterman","year":"2018","journal-title":"Natl Vital Stat Rep"},{"key":"zoi231589r1","unstructured":"Guttmacher Institute. An overview of abortion laws. April 24, 2023. Accessed April 29, 2023. https:\/\/www.guttmacher.org\/state-policy\/explore\/overview-abortion-laws"},{"key":"zoi231589r2","unstructured":"Tracking abortion bans across the country. New York Times. May 22, 2023. Accessed April 29, 2023. https:\/\/www.nytimes.com\/interactive\/2022\/us\/abortion-laws-roe-v-wade.html"},{"key":"zoi231589r4","unstructured":"US Food and Drug Administration. Risk evaluation and mitigation strategies. May 16, 2023. Accessed April 29, 2023. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/risk-evaluation-and-mitigation-strategies-rems"},{"key":"zoi231589r5","unstructured":"US Food and Drug Administration. Approved risk evaluation and mitigation strategies (REMS)\u2014isotretinoin iPLDEGE. March 24, 2023. Accessed April 29, 2023. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/rems\/index.cfm?event=RemsDetails.page&REMS=24"},{"key":"zoi231589r10","unstructured":"US Food and Drug Administration. FDA briefing document: risk evaluation and mitigation strategy (REMS) for isotretinoin products: \u201ciPLEDGE REMS.\u201d March 2023. Accessed May 12, 2023. https:\/\/www.fda.gov\/media\/166485\/download"},{"key":"zoi231589r11","unstructured":"Guttmacher Institute. Induced abortion in the United States. September 2019. Accessed July 20, 2023. https:\/\/www.guttmacher.org\/fact-sheet\/induced-abortion-united-states"},{"key":"zoi231589r26","unstructured":"Centers for Medicare & Medicaid Services. Core set of Children\u2019s Health Care Quality Measures for Medicaid and CHIP\u2014technical specifications and resource manual for federal fiscal year 2022 reporting. March 2022. Accessed November 26, 2022. https:\/\/www.medicaid.gov\/medicaid\/quality-of-care\/performance-measurement\/adult-and-child-health-care-quality-measures\/child-core-set-reporting-resources\/index.html"},{"key":"zoi231589r28","unstructured":"Schoenfeld-Walker? A. Most abortion bans include exceptions\u2014in practice, few are granted. New York Times. January 21, 2023. Accessed July 20, 2023. https:\/\/www.nytimes.com\/interactive\/2023\/01\/21\/us\/abortion-ban-exceptions.html#:~:text=Many%20anti%2Dabortion%20lawmakers%20felt,incomplete%20skulls%20or%20missing%20kidneys"},{"key":"zoi231589r29","unstructured":"Hackney? D. I\u2019m a high-risk obstetrician, and I\u2019m terrified for my patients. New York Times. July 5, 2022. Accessed July 5, 2022. https:\/\/www.nytimes.com\/2022\/07\/05\/opinion\/ob-gyn-roe-v-wade-pregnancy.html?searchResultPosition=1"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2814502\/winterstein_2024_oi_231589_1706171011.44251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T16:32:48Z","timestamp":1706805168000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2814502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.54298","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}